Skip to NavigationSkip to content

Novartis to provide ‘no-profit’ generics to low income countries to help combat COVID-19

Published on 16/07/20 at 10:56am
Photo by Andrew from Flickr

The Sandoz division of Novartis will not make a profit on the 15 generics it is making available to developing nations to help them deal with the coronavirus pandemic.

This includes medicines that will range from steroids to antibiotics and diarrhea pills, which will be distributed to 79 countries the World Bank lists as low to lower-middle income.  The company said it is doing this to help keep vulnerable healthcare systems in Africa, Asia, South America and Eastern Europe from becoming overloaded.

Lutz Hegemann, the Chief Operating Officer at Novartis, said: “We shouldn’t underestimate the stress that COVID puts particularly on fragile health systems. We are not targeting classical commercial distribution channels, but very direct channels, to influence that to the extent we can.”

However, the company’s hydroxychloroquine generic will not be included after some clinical trials investigating its effectiveness in treating COVID-19 concluded it did not work or/and was possibly dangerous. The FDA recently revoked its Emergency Use Authorisation, but Novartis continues to provide it for trials at various world governments request.

Conor Kavanagh

Comments

I appreciate Novartis’s work to provide low price generic medicine to support country in this pandemic time.

Regards, Ida. http://www.assignmenthelpfolks.com/marketing/

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches